The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice
- PMID: 16100156
- DOI: 10.1378/chest.128.2.698
The impact of positron emission tomography on clinical decision making in a university-based multidisciplinary lung cancer practice
Abstract
Introduction: Positron emission tomography (PET) scanning has gained increasing application as a diagnostic and staging tool in the evaluation of lung cancer. Although PET scanning has been demonstrated to be a cost-effective adjunct to lung cancer diagnosis, its global impact on clinical decision making has not been assessed.
Study objectives: To evaluate the impact of the systematic use of PET scanning on clinical decision making.
Design: Retrospective study.
Setting: A university-based multidisciplinary lung cancer practice.
Patients: All patients undergoing diagnostic or staging PET scans from December 31, 2000, to December 31, 2002.
Interventions: None.
Measurements and results: One hundred ninety-eight patients underwent PET for diagnosis (161 patients) or staging (37 patients). PET scan results and clinical outcomes were retrospectively reviewed to determine the frequency with which PET scan findings (1) upstaged patients, (2) downstaged patients, (3) changed the diagnostic workup, (4) altered therapy, (5) resulted in a significant additional diagnosis, and (6) triggered evaluations that ultimately proved fruitless. PET upstaged 32 of 198 patients (16.2%) and downstaged 12 patients (6.1%), facilitating curative resection in 4 patients. Overall, PET scan findings changed the stage in 44 patients (22.2%). PET scan findings changed diagnostic management in 105 of 198 patients (53%), among whom biopsy was deferred in 65 patients (61.9%) and was triggered or guided in 40 patients (38.1%). PET scan findings altered treatment decisions in 38 patients (19.2%), leading to neoadjuvant therapy in 6 patients and resection in 5 patients, and forestalling noncurative thoracotomy in 6 patients. PET scan findings prompted or redirected chemotherapy or radiotherapy in the remainder of the patients. Overall, PET scan findings changed management in 143 patients (72.2%). PET scan findings triggered additional diagnostic testing in 32 patients (16.2%), resulting in no new diagnosis in 16 patients (50%) and a critical change in management in 7 patients (21.9%). PET scan findings were solely responsible for a significant non-lung cancer diagnosis in eight patients (4%).
Conclusions: Systematically applied PET scanning has a significant impact on patient management, altering diagnostic or therapeutic interventions in 72.2% of patients, changing staging in 22.2% of patients, and identifying serious unsuspected diagnoses in 4.0% of patients, with potentially life-saving consequences in 2.0%. Key Words: diagnosis; lung neoplasms; positron emission tomography.
Comment in
-
Impact of positron emission tomography on clinical decision making.Chest. 2006 Jul;130(1):300-1. doi: 10.1378/chest.130.1.300-a. Chest. 2006. PMID: 16840418 No abstract available.
Similar articles
-
The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer.Lung Cancer. 2009 Jun;64(3):301-7. doi: 10.1016/j.lungcan.2008.09.006. Epub 2008 Nov 11. Lung Cancer. 2009. PMID: 19004519
-
Can positron emission tomography be used as a staging tool for small-cell lung cancer?Clin Lung Cancer. 2008 Jan;9(1):30-4. doi: 10.3816/CLC.2008.n.005. Clin Lung Cancer. 2008. PMID: 18282355
-
Optimal anatomic coverage for CT in staging lung cancer: lessons from PET-CT correlation.Lung Cancer. 2011 Jul;73(1):59-62. doi: 10.1016/j.lungcan.2010.10.021. Epub 2010 Nov 20. Lung Cancer. 2011. PMID: 21094559
-
Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer.Chest. 2004 Nov;126(5):1656-66. doi: 10.1378/chest.126.5.1656. Chest. 2004. PMID: 15539740 Review.
-
[PET scanning in the initial assessment of lung cancer].Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S43-8. Rev Mal Respir. 2005. PMID: 16340835 Review. French.
Cited by
-
18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports.Leuk Lymphoma. 2010 Mar;51(3):439-46. doi: 10.3109/10428190903560198. Leuk Lymphoma. 2010. PMID: 20141442 Free PMC article.
-
Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.JAMA. 2014 Sep 24;312(12):1227-36. doi: 10.1001/jama.2014.11488. JAMA. 2014. PMID: 25247519 Free PMC article. Review.
-
Positron emission tomography in the management of lung cancer.Ann Thorac Med. 2007 Apr;2(2):69-76. doi: 10.4103/1817-1737.32235. Ann Thorac Med. 2007. PMID: 19727351 Free PMC article.
-
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):36-44. doi: 10.1007/s00259-006-0186-3. Epub 2006 Aug 1. Eur J Nucl Med Mol Imaging. 2007. PMID: 16896664
-
Molecular imaging for personalized cancer care.Mol Oncol. 2012 Apr;6(2):182-95. doi: 10.1016/j.molonc.2012.02.005. Epub 2012 Mar 10. Mol Oncol. 2012. PMID: 22469618 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical